Glass Jacobson Investment Advisors llc Acquires New Position in Axon Enterprise, Inc $AXON

Glass Jacobson Investment Advisors llc bought a new position in Axon Enterprise, Inc (NASDAQ:AXON) in the second quarter, Holdings Channel reports. The firm bought 317 shares of the biotechnology company’s stock, valued at approximately $262,000.

A number of other hedge funds have also bought and sold shares of AXON. Sage Mountain Advisors LLC purchased a new position in shares of Axon Enterprise in the second quarter worth $294,000. Washington Trust Advisors Inc. increased its position in shares of Axon Enterprise by 44.7% in the 2nd quarter. Washington Trust Advisors Inc. now owns 55 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 17 shares during the period. West Michigan Advisors LLC purchased a new position in Axon Enterprise in the 2nd quarter worth $219,000. Asset Management One Co. Ltd. lifted its position in Axon Enterprise by 1.6% during the 2nd quarter. Asset Management One Co. Ltd. now owns 30,774 shares of the biotechnology company’s stock worth $25,479,000 after acquiring an additional 489 shares during the period. Finally, 180 Wealth Advisors LLC grew its stake in Axon Enterprise by 35.2% during the 2nd quarter. 180 Wealth Advisors LLC now owns 519 shares of the biotechnology company’s stock valued at $430,000 after purchasing an additional 135 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $735.95 on Friday. The company has a market capitalization of $57.77 billion, a PE ratio of 181.72, a price-to-earnings-growth ratio of 28.58 and a beta of 1.41. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The company’s fifty day moving average price is $733.17 and its 200 day moving average price is $725.28. Axon Enterprise, Inc has a 1 year low of $422.38 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. During the same quarter in the previous year, the company earned $1.20 earnings per share. The firm’s revenue for the quarter was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. On average, research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Wolfe Research began coverage on Axon Enterprise in a research note on Monday, July 7th. They issued an “outperform” rating for the company. Piper Sandler assumed coverage on shares of Axon Enterprise in a research note on Tuesday, September 23rd. They set an “overweight” rating and a $893.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $870.00 price objective on shares of Axon Enterprise in a research note on Wednesday, September 24th. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Finally, UBS Group reaffirmed a “neutral” rating and issued a $840.00 price target (up from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average target price of $841.64.

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 15,919 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the transaction, the president owned 238,379 shares in the company, valued at approximately $177,892,712.54. This represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Brittany Bagley sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $713.88, for a total value of $3,569,400.00. Following the completion of the sale, the chief financial officer directly owned 93,592 shares in the company, valued at approximately $66,813,456.96. The trade was a 5.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 59,932 shares of company stock worth $45,115,616 in the last ninety days. 4.40% of the stock is owned by corporate insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.